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Abstract
Background: In previous work, we built the Drug Ontology (DrOn) to support comparative effectiveness research
use cases. Here, we have updated our representation of ingredients to include both active ingredients (and their
strengths) and excipients. Our update had three primary lines of work: 1) analysing and extracting excipients, 2)
analysing and extracting strength information for active ingredients, and 3) representing the binding of active
ingredients to cytochrome P450 isoenzymes as substrates and inhibitors of those enzymes.
Methods: To properly differentiate between excipients and active ingredients, we conducted an ontological
analysis of the roles that various ingredients, including excipients, have in drug products. We used the value
specification model of the Ontology for Biomedical Investigations to represent strengths of active ingredients and
then analyzed RxNorm to extract excipient and strength information and modeled them according to the results of
our analysis. We also analyzed and defined dispositions of molecules used in aggregate as active ingredients to
bind cytochrome P450 isoenzymes.
Results: Our analysis of excipients led to 17 new classes representing the various roles that excipients can bear. We
then extracted excipients from RxNorm and added them to DrOn for branded drugs. We found excipients for 5,743
branded drugs, covering ~27 % of the 21,191 branded drugs in DrOn.
Our analysis of active ingredients resulted in another new class, active ingredient role. We also extracted strengths
for all types of tablets, capsules, and caplets, resulting in strengths for 5,782 drug forms, covering ~41 % of the
14,035 total drug forms and accounting for ~97 % of the 5,970 tablets, capsules, and caplets in DrOn.
We represented binding-as-substrate and binding-as-inhibitor dispositions to two cytochrome P450 (CYP)
isoenzymes (CYP2C19 and CYP2D6) and linked these dispositions to 65 compounds. It is now possible to query
DrOn automatically for all drug products that contain active ingredients whose molecular grains inhibit or are
metabolized by a particular CYP isoenzyme.
DrOn is open source and is available at http://purl.obolibrary.org/obo/dron.owl.
Background
In previous work, we built the Drug Ontology (DrOn) to
support comparative effectiveness research use cases and
reported on its theoretical basis, the methodology we
used to build it, and its ability to meet the use cases [1–3].
Motivated by critiques and requests from end-users of
DrOn of its representation of ingredients, we describe
how we have improved the accuracy and coverage of our
representation of ingredients.
The work involved three major components. The first
component was the inclusion of excipients. Although
active ingredients and their strengths have obvious
effects on the efficacy of a drug, excipients also influence
drug effects in significant ways [4–6]. Additionally, it is
not uncommon for excipients to cause allergic reactions
in patients [7, 8]. The second component was the im-
provement and extension of the representation of active
ingredients, including the addition of strength informa-
tion. The last component was representing for the first
time in an open-access, machine-readable ontology the
binding disposition of certain molecules to cytochrome
P450 (CYP) isoenzymes as substrates and / or inhibitors.
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Methods
In Hogan et al. [1], we differentiated between excipients
and active ingredients but did not define or represent their
differences explicitly. To do so, we first conducted an
ontological analysis of the roles various ingredients have
in drug products. We also represented strengths of active
ingredients according to the value specification model of
the Ontology for Biomedical Investigations (OBI) [9]. We
documented and reviewed our definitions and proposed
classes and their axiomatizations on the DrOn wiki page
[10]. Once complete, we then analyzed RxNorm [11] to
extract excipient and strength information and modeled
them according to the results of our analysis.
Analysis of excipients and method of extracting them
from RxNorm
We reviewed publicly available sources of information
about the various roles of excipients and conducted an
ontological analysis of them from the realist perspective.
Excipients have numerous roles that aid in the manufac-
ture, administration, identification, and preservation of
drug products. To represent these roles, we defined the
following and included them in DrOn: excipient role, lu-
bricant excipient role, glidant excipient role, anti-
adherent excipient role, anti-friction excipient role, bind-
ing excipient role, coating excipient role, protective coat-
ing excipient role, enteric coating excipient role,
administration coating excipient role, flavor coating ex-
cipient role, lubricant coating excipient role, color excipi-
ent role, flavor excipient role, disintegrant excipient role,
preservative excipient role, sorbent excipient role, and ve-
hicle excipient role. We present the results of our onto-
logical analysis, including textual and axiomatic
definitions of these terms in the Results section.
RxNorm contains excipient information that it obtains
from Structured Product Labels (SPLs). SPLs are a digital
form of the physical product label that the Food and Drug
Administration (FDA) collects from drug manufacturers.
RxNorm includes information extracted from SPLs and
stores it with a source abbreviation (used to identify the
source of the information) of ‘MTHSPL’. RxNorm in-
cludes a ‘has_inactive_ingredient’ relationship extracted
from the SPLs, which we used to identify the excipients
for drug products in DrOn. Since DrOn previously only
contained information from RxNorm under the source
abbreviation ‘RXNORM’—which is data collected from
the other sources and then normalized—we needed to
match the MTHSPL atoms to the appropriate RxNorm
concepts and then to the appropriate DrOn entities. It
should be noted that the MTHSPL data is denoted source
restriction level 0 in RxNorm, meaning it is licensed for
creation of derivative open source works.
We also make extensive use of Semantic Clinical Drugs
(SCDs) and Semantic Branded Drugs (SBDs) in RxNorm.
Each SCD represents a unique combination of active in-
gredients, their strengths, and dose form. An SBD repre-
sents everything that an SCD represents plus information
about a drug product’s trade name.1 Both SCDs and SBDs
are the result of RxNorm’s normalization process, and
thus are assigned concept identifiers (RxCUIs).
Using the April, 2015, release of RxNorm, we:
(1) Found all the atoms in the RXNREL table that have
a source abbreviation of ‘MTHSPL’ and a
relationship type of ‘has_inactive_ingredient’.
(2) Mapped both atoms to the appropriate RxNorm
concept unique identifier (RxCUI).
(3) Mapped the RxCUIs to atoms within the
RXNCONSO table that have a source abbreviation
of ‘RXNORM’ and a term type of ‘IN’ (for
ingredients) or ‘SBD’ (for drugs).
(4) Mapped the RxCUIs to DrOn drug product and
ingredient classes that have the same RxCUI
annotated on them.
This process gave us a mapping that connected
branded drugs in DrOn to various excipient ingredients.
Because we used unique identifiers from both DrOn and
RxNorm (RxCUIs) to create this mapping, the process
was straightforward, and required no manual resolution
of ambiguity.
We excluded excipients linked to SCDs in RxNorm
because we found that multiple generic and branded
products extracted from SPLs were linked to SCDs but
not SBDs, resulting in SCDs being linked to all the excipi-
ents of many drug products at the same time. For ex-
ample, ‘dimethicone 10 MG/ML Topical Cream’ (RxCUI
200010) is associated with 39 different SPL drug products,
including many branded drugs like ‘Proshield Glove Skin
Protectant’ (RxAUI 4232431) or ‘Better Than Nature Eye
Essence’ (RxAUI 4660113), for which there does not also
exist in RxNorm a SBD. Future work involves represent-
ing these products distinctly in DrOn.
Analysis of active ingredients and extracting their strengths
from RxNorm
Although in Hogan et al. [1], we recognized the ac-
tive ingredient as being a scattered molecular aggre-
gate as defined and represented in the Ontology of
Biomedical Investigations, the Web Ontology Lan-
guage (OWL) representation of DrOn lagged behind
this recognition. Our first major change, then, was to
update the OWL representation of active ingredients
from, for example:: (has_proper_part some
ramipril) was updated to (has_proper_part
some (‘scattered molecular aggregate’
and (‘has granular part’ some
ramipril))).
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The second update was to define ‘active ingredient’ as
a role (see Results) and assert that the scattered molecu-
lar aggregate is the bearer of this role:
has_proper_part some (‘scattered molecu-
lar aggregate’ and (‘has granular part’
some ramipril) and (‘is bearer of’ some
‘active ingredient role’))
The third update was to begin capturing strength
information starting with the most prevalent and easi-
est case: tablets, capsules, and caplets. DrOn already
contains all of the active ingredients found within
RxNorm with a source abbreviation of ‘RXNORM’. In
RxNorm, strengths are related to Semantic Drug
Components (SCDCs), which are not represented in
DrOn. RxNorm creates one SCDC per unique com-
bination of active ingredient and strength and also re-
lates a drug to its active ingredients via SCDCs with
a consists_of relationship. We therefore carried out
the following steps to map the active ingredients of
drug products in DrOn to their appropriate strengths.
We did this using the April, 2015, version of RxNorm
as follows:
(1) Mapped the clinical drugs within DrOn to RxNorm
concepts in the RXNCONSO table with a source
abbreviation of ‘RXNORM’ and a term type of
‘SCD’ using the annotated RxCUI.
(2) Mapped the SCDs from the previous step to the
appropriate concepts with a source abbreviation of
‘RXNORM’, a relationship of ‘consists_of ’, and term
type of ‘SCDC’ using the RXNCONSO and
RXNREL tables.
(3) Mapped the SCDC concepts from the previous step
to the appropriate concepts with a source
abbreviation of ‘RXNORM’, a relationship of
‘has_ingredient’, and term type of ‘IN’ using the
RXNCONSO and RXNREL tables.
(4) Mapped the IN concepts to the ingredients within
DrOn using its RxCUI.
(5) Pulled out the strength of the SCDC from the
RXNSAT table using the ‘RXN_STRENGTH’
attribute name.
This process gave us a mapping between clinical drug,
ingredient, and strength that we then used to build the
OWL representation as illustrated below.
In DrOn, we place branded drug classes (corre-
sponding to SBDs) as subclasses of classes that repre-
sent preparations of specific active ingredients, their
strengths, and dose form (corresponding to SCDs).
Thus, we only needed create axioms representing
strengths at the SCD-equivalent level since these ax-
ioms are inherited by classes further down the hier-
archy and thus apply to the branded drugs.
Results
Our work has three key contributions: 1) a realist analysis
and resulting ontological representation of drug excipients
and the various roles they play, 2) a realist analysis of ac-
tive ingredients and their strengths, and 3) a realist ana-
lysis of cytochrome P450 isoenzyme binding. In the rest of
this section, we will describe them in detail.
Realist analysis of drug excipients
The excipients used in drug products have varied roles.
We define an excipient role as a role of a scattered mo-
lecular aggregate in aiding the manufacture, prolonging
the shelf life, aiding the identification, or ensuring proper
administration of a drug product.
Before creating a new term, we surveyed other OBO
Foundry resources for existing terms that met our needs.
The Chemical Entities of Biological Interest (ChEBI)
ontology [12] defines an excipient role as a generally
pharmacologically inactive substance that is formulated
with the active ingredient of a medication.
This definition would seem to be inline with our
usage, but the term seems to be used within ChEBI to
apply to individual molecules rather than aggregates,
meaning every molecule of magnesium stearate in some
drug tablet has its own role to, for instance, decrease the
adhesion between the other ingredient molecules and
the manufacturing machinery. Although it is true that
each molecule has some disposition that, in aggregate,
leads to lower adhesion, a single molecule is not suffi-
cient when added to a drug preparation by itself. Its
intended usage, and thus its role, can only be realized in
the aggregate, and thus we assign the role to the aggre-
gate of all magnesium stearate molecules used in the
manufacture of the drug product (not just those mole-
cules remaining).
Furthermore, an excipient role as defined in ChEBI is
too general. An excipient is added to a drug product
with a specific intent, unless we are to count contami-
nants. If, in the process of manufacturing a drug prod-
uct, some minor contaminant makes it into a gel
capsule, it is not an excipient. Therefore, assigning the
role of exicpient to all things formulated with the active
ingredient is too broad.
In addition to a general excipient role, we have identi-
fied sixteen specific subtypes of excipients based on spe-
cific uses. Figure 1 shows the various types of excipient
roles and the relations between them.
Lubricant excipient role: An excipient role that is real-
ized by a process of drug administration or a process of
drug manufacturing and results in either 1) decreased
adhesion between drug ingredients and manufacturing
equipment or between drug ingredients and some part of
an organism; 2) decreased friction between drug ingredi-
ents and manufacturing equipment or between drug
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ingredients and some part of an organism; or 3) de-
creased cohesion among particles within the drug
preparation.
Lubricant excipients are added to drug preparations to
prevent ingredients from sticking to themselves (cohe-
sion) and to other things with which they come into
Fig. 1 Excipients. The various excipient roles and their is-a relationships
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contact (adhesion). Common lubricants are minerals like
magnesium stearate. There are three major subtypes of lu-
bricants: glidants (glidant excipient role), anti-adherents
(anti-adherent excipient role), and anti-friction lubricants
(anti-friction excipient role). In defining the three subtypes,
we make the distinction between adhesion (which is a
steady or firm atachment) and friction (which is the force
that provides resistance to relative motion). To see the dif-
ference consider a wet piece of paper: it will adhere to a
plate of glass, but offer minimal friction to movement
along the glass.
Glidant excipient role: A lubricant excipient role that
is realized by a process of drug administration or a
process of drug manufacturing and results in decreased
cohesion or friction among particles within a drug
preparation.
A glidant is added to a drug product to reduce cohe-
sion and interparticle friction. Common glidants are talc
and magnesium carbonate.
Anti-adherent excipient role: A lubricant excipient role
that is realized by a process of drug administration or a
process of drug manufacturing and results in decreased
adhesion between drug ingredients and manufacturing
equipment or between drug ingredients and some part of
an organism.
Anti-adherents are added to drug products to decrease
the tendency of drug molecules to adhere to manufac-
turing equipment or some body part such as the throat
or esophagus during swallowing.
Anti-friction excipient role: A lubricant excipient that
is realized by a process of drug administration or a
process of drug manufacturing and results in decreased
friction between drug ingredients and manufacturing
equipment or between drug ingredients and some part of
an organism.
Anti-friction excipients are added to decrease either
internal friction (i.e., friction between ingredient parti-
cles) or friction between the drug ingredients or product
and some other object, such as manufacturing equip-
ment or some body part.
Binding excipient role: An excipient role that is real-
ized by a process of drug manufacturing and results in
increased volume or cohesion of the drug product.
Binding excipients are added to drug preparations to
1) bind active ingredients together, and 2) increase the
volume of the preparation (which is especially important
for formulations with otherwise small volumes). Com-
mon binding agents are saccharides (like sucrose) or
synthetic compounds like polyethylene glycol.
Coating excipient role: An excipient role borne by an
aggregate of molecules on the surface of a solid drug
product that is realized by a process of delaying inter-
action between entities outside the drug product and the
other ingredients in the drug product.
Coatings are extremely common excipients, added to
protect the drug preparation from destruction or con-
tamination, to ease administration by making it easier to
consume, or to improve flavor. There are five major sub-
types of coating excipient.
Protective coating excipient role: A coating excipient
role that is realized by delaying denaturation, disintegra-
tion, or some other method of destruction of a drug prep-
aration including its active ingredients.
A protective coating acts against destruction or
contamination of a drug preparation by keeping the
other drug ingredients, especially active ingredients,
away from potentially reactive substances like oxygen,
water, and various forms of electromagnetic radiation
(e.g., light).
Enteric coating excipient role: A protective coating ex-
cipient role that is realized by a process of delaying release
of one or more active ingredients from the drug product
until some targeted time or location, typically the small or
large intestine, within an organism.
An enteric coating also protects the drug preparation
from destruction or contamination, but also is designed
to disintegrate on a controlled timeline or in a particular
place. For instance, some enteric coatings are designed
to withstand the relatively high PH of the stomach, but
break down in the relatively low PH of the large intes-
tine, allowing an ingredient that would otherwise be
destroyed by or absorbed by the stomach to be absorbed
in the intestine.
Administration coating excipient role: A coating ex-
cipient role that is realized by facilitating a process of
drug administration.
An administration coating is one that somehow im-
proves administration of the drug, by for example mak-
ing insertion or consumption of the drug easier or
masking undesirable flavors.
Flavor coating excipient role: An administration coat-
ing excipient role that is realized by a drug manufactur-
ing process that results in the drug product bearing a
particular flavor quality.
Flavored coatings make it more palatable to consume
a drug product by improving its taste, often by masking
the unpleasant taste of the active ingredients.
Lubricant coating excipient role: An administration
coating excipient role that is realized by decreased fric-
tion between the drug preparation and some part of an
organism during drug administration.
A lubricant coating makes it easier to consume or in-
sert a drug product by decreasing the friction or adhe-
sion between the drug preparation and some body part
such as the throat or esophagus.
Color excipient role: An excipient role that is realized
by a process of drug manufacturing that results in a par-
ticular, desired color quality of the drug product.
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Colored excipients are added to a drug preparation to
make various kinds of drugs more easily identifiable by
sight to decrease the possibility of using the wrong dos-
age or wrong drug product altogether.
Flavor excipient role: An excipient role that is realized
by a process of drug manufacturing that results in the
drug product bearing a particular flavor quality.
Like a flavored coating, a flavored excipient is added
to the drug preparation to make it more palatable. This
is especially important for drug products targeted to-
wards children to make administration easier.
Disintegrant excipient role: An excipient role that is re-
alized by a process of drug administration followed by
the drug product breaking apart.
A disintegrant is added to a drug preparation to cause
it to break apart whenever it is introduced to moisture.
A disintegrant can improve administration (such as oral
medications that dissolve in the mouth) or improve up-
take of active ingredients for example, in the intestine.
Preservative excipient role: An excipient role that is re-
alized by increasing the duration of time that a drug
product is effective or by inhibiting contamination of the
drug product with a microorganism.
Preservatives are added to a drug preparation to in-
crease the lifetime of the drug preparation. Examples in-
clude antioxidants such as ascorbic acid that prevent
oxidation-reduction reactions that change active ingredi-
ents into inactive compounds and methyl paraben which
is an antimicrobial preservative.
Sorbent excipient role: An excipient role that is real-
ized by its bearer binding with water in the environment
to prevent water binding with other ingredients in the
drug product.
Sorbents are added to protect the drug preparation
from destruction or disintegration by water. A common
example is a desiccant, which is a sorbent that prevents
absorption of water into the drug product.
Vehicle excipient role: An excipient role that is realized
by a completed process of the active ingredient reaching its
intended destination during drug administration.
Generally, vehicles are the media in which the active
ingredient is dispersed to facilitate the active ingredient
reaching its intended target tissue. For example, active
ingredients that exist in solid form such as a powder
cannot be directly injected intravenously without causing
damage to veins or becoming emboli that cause damage
to the lungs. Thus they are dissolved in solution for safe
and proper administration. Other examples of vehicles
include creams, ointments, lotions, gels, and solvents for
ophthalmic, otic, and oral solutions.
Having reviewed and defined the major subtypes of ex-
cipients, we next illustrate how we represent molecular
aggregates and their excipient roles in the DrOn OWL
files. Consider a drug tablet that contains povidone and
pregelatinized starch as excipients. We axiomatize this
tablet as follows:
tablet and (has_proper_part some ('scat-
tered molecular aggregate' and
(has_granular_part some povidone)
and
(bearer_of some 'binding excipient
role'))) and
(has_proper_part some ('portion of
pregelatinized starch' and
(bearer_of some 'binding excipient
role')))
Our extraction of excipient information from RxNorm
resulted in the representation of excipients for 5,743
branded drugs, covering ~27 % of the 21,191 total num-
ber found in DrOn. There are a total of 35,455 different
drug product–excipient relationships. By comparison,
there are 22,845 relationships between drug products
and active ingredients. The main reasons there are fewer
relationships between drugs and active ingredients than
there are between drugs and excipients is that there are
fewer active ingredients and that active ingredients are
specified at a higher level in the taxonomy of drugs. Ac-
tive ingredients are defined at the level of clinical drug
form (for example, furosemide oral tablet) whereas ex-
cipients exist at the level of branded drug (more specific
than clinical drug form), because each brand of a drug
product such as furosemide 20 mg oral tablet typically
contains a different set of excipients.
Realist analysis of active ingredients
Although DrOn has always included active ingredients,
we have updated the representation to more accurately
reflect reality and to allow us to add strengths to drug
products. To do so, it was necessary to represent active
ingredient role, which we define as a role borne by an
aggregate of molecules that is a proper part of a drug
product and that is realized by (1) administration of the
drug to an organism followed by (2) some change in the
structure or functioning of some part of the organism or
its endosymbiotic organisms.
This definition meets several criteria we identified dur-
ing our analysis of active ingredients. First, it is a
realizable entity. Note that an active ingredient does
nothing until and unless the drug product is appropri-
ately administered. Second, it is a role rather than a dis-
position (or, more specifically, a function). Some
ingredients can serve as either an excipient or an active
ingredient depending on the specific drug product. For
example, calcium carbonate is an active ingredient in
certain antacid tablets, but an excipient in other prod-
ucts. Furthermore, calcium carbonate neither evolved
nor was designed to neutralize acids (a key criterion of
functions per BFO). Of course, there is some disposition
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at the molecular level that the realization of the active
ingredient role depends on; in the case of calcium car-
bonate, its physical makeup causes it to react with
strong acids, releasing carbon dioxide. But this dispos-
ition inheres in each individual molecule of calcium car-
bonate whereas the active ingredient role inheres in the
entire aggregate in the tablet: clinically signficant acid
neutralization occurs only with the aggregate delivered
via the tablet.
We represent the active ingredient role in OWL in a
manner similar to how we represent the excipient role.
We represent a drug tablet that has acetaminophen as
an active ingredient with a strength of 325 MG as the
following:
tablet and (has_proper_part some ('scat-
tered molecular aggregate' and
(has_granular part some acetaminphen)
and
(bearer_of some ‘active ingredient
role') and





We added strengths to 5,782 clinical drugs, cover-
ing ~41 % of the 14,035 total number, and account-
ing for ~97 % of the 5,970 tablets, capsules, and
caplets in DrOn. Representing strengths for drug
products in other dose forms (e.g., injectable solu-
tions, creams, lotions, etc.) is future work.
Realist analysis of cytochrome P450 isoenzyme binding
When a particular molecule binds to one of the isoen-
zymes in the cytochrome P450 (CYP) family, it does so
as substrate, inhibitor, or both. Induction of CYP isoen-
zymes does not involve binding to individual enzyme
molecules themselves, but rather it involves increasing
transcription of CYP isoenzyme genes so that more indi-
vidual enzymes come into existence. We could not find
in the literature any case where molecular binding of a
small molecule to a CYP isoenzyme induced or facili-
tated the activity of the isoenzyme.
We therefore represent binding of a small molecule to
a CYP isoenzyme as a disposition of the molecule. It is
not a function because the small molecule neither
evolved nor was designed to have this binding effect. It
is not a role because the tendency to bind is internal to
the physical structure of the molecule itself. Nothing ex-
ternal or socially-designated causes the binding tendency
to exist (note: we are loosly using the word ‘tendency’
here to equate to what BFO calls ‘realizable entity’).
We subdivide the binding disposition based on
whether its realization results in transformation of the
molecule into another type of molecule (that is, metab-
olism of the molecule into something else) versus
whether its realization causes inhibition of the isoen-
zyme in metabolizing other small molecules. We note
that many types of molecules used as active ingredient
drugs have both substrate and inhibitory dispositions
(for example, esomeprazine is both an inhibitor and sub-
strate of CYP2C19).
To represent enzyme binding, we identified an enzyme
binding class in the Gene Ontology (GO) and imported
it into DrOn via the Minimum Information to Reference
an External Ontology Term (MIREOT) methodology
[13]. Its definition is the following: interacting selectively
and non-covalently with any enzyme. For completeness,
we also import protein binding and binding, the parent
and grandparent of enzyme binding, respectively, into
DrOn.
For binding to the active site of an enzyme, we were
unable to identify a candidate term from any other real-
ist ontology. Thus, we created the term enzyme active
site binding disposition, which we defined as a dispos-
ition borne by some molecular entity that is realized by
binding to some enzyme and being destroyed in a process
that realizes some function of said enzyme. Similarly, we
could not find and therefore created the term function-
inhibiting enzyme-binding disposition, and defined it as a
disposition borne by some molecular entity that is real-
ized by 1) binding to some enzyme and 2) subsequent in-
ability of the active site of the enzyme to bind its
substrate(s).
We represented substrate and inhibitory binding dis-
positions for CYP2C19 and CYP2D6, because these are
the major two isoenzymes targeted by the personalized
medicine program at the University of Florida [14, 15].
We represented these in OWL by adding axioms as fol-
lows, using CYP2C19 inhibitory disposition as an ex-
ample, to the molecular entities for which they are
applicable:
subclassOf (bearer_of some function-
inhibiting CYP2C19 binding disposition)
In total, we added CYP2C19 and CYP2D6 binding dis-
positions to 65 molecules, with some of them being the
bearer of both an inhibitory and substrate definition
(Table 1). Our source of data for the types of molecules
that bear the particular types of binding dispositions was
Table 1 Number of CYP binding dispositions of various types in
DrOn. The total number of molecular entities is 65; many have
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the P450 drug interaction table of the Indiana University
School of Medicine [16].
Discussion
We have significantly updated and improved the repre-
sentation of ingredients in the Drug Ontology. In the
process, we have defined a number of key terms in
DrOn including ‘active ingredient role’, ‘excipient role’,
terms for numerous subtypes of excipient, and various
terms for cytochrome P450 substrate and inhibitory
binding. This representation enables automated algo-
rithms to distinguish active ingredients from excipients
in drug products, as well as determine the strength of
drug products that are capsules, tablets, and caplets.
Given that excipients have important clinical conse-
quences, including hypersensitivity reactions, their inclu-
sion could help improve research on drug products,
pharmacogenomics, and clinical decision support.
A key use of DrOn is in the improvement and
standardization of knowledge of drug-drug interactions
(DDIs) [17]. This work requires accurate representations
of active ingredients with strengths and excipients since
they impact the potential for, likelihood, and severity of
interactions. Our work on CYP isoenzymes further en-
ables query of DrOn for all drug products that contain
an ingredient whose molecular grains bind particular
CYP isoenzymes. A researcher could use these represen-
tations, for example, to identify all patients who are tak-
ing one drug that inhibits a given isoenzyme and
another drug that is metabolized by it, and thus is at risk
for adverse effects of the latter drug (that is, the inhib-
ition caused by the first drug will reduce the metabol-
lism of the second drug, leading to increased levels and
thus increased risk of toxicity).
Other work seeks to infer DDIs based on common
properties including the structure of compounds [18].
Specifically, if some but not all compounds with a given
property or structure X are asserted to have a DDI with
some compound Y, then this method identifies the
remaining compounds with X as candidates for also hav-
ing a DDI with Y. As DrOn is increasingly used for DDI
representation, it will be interesting future work to com-
pare this method applied to DrOn-based DDI represen-
tations vs. other artifacts.
For DrOn’s representation of strengths, we were able
to reuse the value specification of the Ontology of Bio-
medical Investigations as well as its object and datatype
properties. We used the MIREOT Protégé plugin we de-
veloped [13] to include these properties as well as the
units of measure required.
While adding excipients, we discovered that there was a
significant sparsity of branded drugs in RxNorm with ex-
cipient information. The reason is likely that RxNorm
began incorporating SPLs, the current source of excipient
information, only recently in 2012. Additionally, RxNorm
has mapped many drugs with FDA SPLs to Semantic
Clinical Drugs only. For example, ‘dimethicone 10 MG/ML
Topical Cream’ (RxCUI 200010) is associated with 39 dif-
ferent SPL drug products, including many branded drugs
like ‘Proshield Glove Skin Protectant’ (RxAUI 4232431) or
‘Better Than Nature Eye Essence’ (RxAUI 4660113). This
SCD has around 170 different excipients associated with
it. Another example is ‘Dextromethorphan Hydrobromide
2 MG/ML / Guaifenesin 20 MG/ML Oral Suspension’
(RxCUI 1605844), which is associated with ‘Tussin Cough
and Chest Congestion DM Adult’ (RxAUI 6836489). The
excipients linked to these Semantic Clinical Drugs appear
to be a superset of all the excipients of the SPL-derived
drug products that RxNorm links to the SCD. Because
RxNorm does not represent generic drug products, the
excipients of all generic products also appear to be linked
to the SCD. Of course, these observations are likely re-
lated. Further analysis is required.
In the process of defining the active ingredient role,
we added the capability to represent pharmaceutical
strength. We began with tablets, capsules, and caplets
because they represent the total quantity of active ingre-
dient, which is simpler to represent than concentrations.
For other dose forms, RxNorm specifies the quantity of
active ingredient per unit of drug product (e.g., per milli-
liter of solution, per gram of ointment) and the total
quantity of drug product (e.g., 5 mL vial, 25 g tube of
ointment) is not always available from which the total
mass of active ingredients could be derived.
Future Work
We have three primary directions for future work. First,
we intend to increase coverage of excipients and
strengths of active ingredients. Our strength coverage
for the dose forms we used in this analysis is sufficiently
high, but we still need to work out the representation
and then extract strength information for other dose
forms, which are expressed as relative vs. total quantity
of active ingredient. Additionally, we intend to tease out
the excipients that are currently mapped to SCDs in
RxNorm, which requires further analysis.
Second, we intend to represent the induction of CYP
isoenzymes by particular active ingredients in drug prod-
ucts. The inductive effect is indirect through an increased
rate of genetic transcription that creates additional copies
of CYP isoenzymes, rather than through mere binding to
the isoenzyme. It is therefore somewhat more complex to
represent. It is also likely an aggregate effect as opposed a
property of any individual molecule (although dispositions
of the molecules are certainly involved along the way).
Third, we intend to represent therapeutic indications
of drug products. We currently posit that a therapeutic
indication is a function borne by a drug product that is
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realized by a process of administration to an organism,
distribution of one or more active ingredients to some
target tissue, and resulting in some physical change in
the targeted tissue. However, this work requires further
development of use cases and ontological analysis.
Conclusions
In this paper, we describe three primary lines of work: 1)
an update to our representation of active ingredients, in-
cluding adding strengths; 2) a new representation of ex-
cipients; and 3) a new represention of substrate and
inhibitory binding dispositions for CYP2C19 and
CYP2D6. We created new terms and definitions for ex-
cipient role and sixteen different subtypes, the active in-
gredient role, and various terms to represent substrate
and inhibitory binding dispositions for CYP2C19 and
CYP2D6. We also reported on how these terms were
used in the Drug Ontology, and made the updated rep-
resentations available at http://purl.obolibrary.org/obo/
dron.owl.
Endnotes
1And hence only branded drug products, and not generic
drug products, of manufacturers are assigned RxCUIs.
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